Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients

Wong Robert J.; Jain Mamta K.; Shiffman Mitchell L.; Kshirsagar Onkar; Clark Christopher; Vining Caitlin; Thamer Mae

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients

【24h】

Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients

机译：基于保险状况对高效直接代理抗病毒（DAA）在DAA时代的丙型肝炎病毒治疗中的显微访问持续存在：医疗补助受害者的获得令人惊讶地受损

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2017年第1期|共1页
作者
Wong Robert J.; Jain Mamta K.; Shiffman Mitchell L.; Kshirsagar Onkar; Clark Christopher; Vining Caitlin; Thamer Mae;
展开▼
作者单位

Highland Hosp Alameda Hlth Syst Oakland CA USA;

Univ Texas Southwestern Med Ctr Dallas Dallas TX 75390 USA;

Liver Inst Virginia Richmond VA USA;

Med Technol &

Practice Patterns Inst Bethesda MD USA;

Parkland Hlth &

Hosp Syst Dallas TX USA;

Liver Inst Virginia Richmond VA USA;

Med Technol &

Practice Patterns Inst Bethesda MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
专利

1. Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients [J] . Wong Robert J., Jain Mamta K., Shiffman Mitchell L., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：基于保险状况对高效直接代理抗病毒（DAA）在DAA时代的丙型肝炎病毒治疗中的显微访问持续存在：医疗补助受害者的获得令人惊讶地受损
2. P2‐091: Scale up of hepatitis C virus treatment in the era of expanded access to all‐oral direct‐acting antivirals (DAAs): a 9‐year Greek cohort study [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P2-091：扩大丙型肝炎病毒治疗在扩大访问的甲型肝炎病毒治疗（DAAS）中的时代（DAAS）：一个9年的希腊队列研究
3. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment [J] . Wong Robert J., Jain Mamta K., Therapondos George, The American Journal of Gastroenterology . 2018,第9期

机译：种族/民族和保险状况访问丙型肝炎病毒治疗直接代理抗病毒的差异
4. Analyzing the Impact of the CMS Guidance on Assuring Access to Hepatitis C Virus (HCV) Drugs on Utilization of Direct-Acting Antiviral (DAA) Agents [D] . Ferrell, Kelli Walker. 2017

机译：分析CMS指南对确保获得丙型肝炎病毒（HCV）药物对直接作用抗病毒（DAA）药物利用的影响
5. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy [O] . Nicholas Lim, Dupinder Singh, Scott Jackson, 2020

机译：丙型肝炎病毒（HCV）肝移植受者的肝细胞癌复发用预体直接作用抗病毒（DAA）治疗治疗
6. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? [O] . J Bischoff, S Mauss, C Cordes, 2018

机译：直接作用抗病毒（DAA）的丙型肝炎病毒（HCV）治疗的预定结束后12周持续持续的病毒学响应率：HIV繁殖会损害对DAA组合治疗的反应吗？

Disparate Access Based on Insurance Status to Highly Effective Direct Acting Antivirals (DAA) for Hepatitis C Virus Treatment in the Post-DAA Era Persists: Alarmingly Impaired Access in Medicaid Recipients

著录项

引文网络

相似文献

相关主题

期刊订阅